Oscotec Inc. (KOSDAQ:039200)

Market Cap	1.11T
Revenue (ttm)	34.01B
Net Income (ttm)	876.53M
Shares Out	38.25M
EPS (ttm)	23.00
PE Ratio	1,269.81
Forward PE	83.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	365,774
Average Volume	391,326
Open	30,900
Previous Close	31,200
Day's Range	28,650 - 31,250
52-Week Range	21,600 - 45,850
Beta	1.23
RSI	45.93
Earnings Date	Mar 19, 2025

About Oscotec

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Employees: 51
• Stock Exchange: KOSDAQ
• Ticker Symbol: 039200

Financial Performance

In 2023, Oscotec's revenue was 4.95 billion, a decrease of -2.20% compared to the previous year's 5.06 billion. Losses were -24.28 billion, -0.61% less than in 2022.